Condition (MeSH)
Glomerulonephritis, Membranoproliferative
ClinicalTrials.gov lists 31 trials for Glomerulonephritis, Membranoproliferative or a narrower condition beneath it. Apellis Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
31 of the 31 trials are tagged with Glomerulonephritis, Membranoproliferative itself; the rest are tagged with a narrower condition beneath it.
When did Glomerulonephritis, Membranoproliferative trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 5 |
| 2017 | 4 |
| 2014 | 2 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 17 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Glomerulonephritis, Membranoproliferative trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 12 |
| Phase 3 | 6 |
| Not applicable | 3 |
| Observational | 3 |
| Expanded access | 1 |
How many Glomerulonephritis, Membranoproliferative trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 8 |
| Active, not recruiting | 2 |
| Completed | 14 |
| Approved for marketing | 1 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Glomerulonephritis, Membranoproliferative trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Apellis Pharmaceuticals, Inc. | 5 |
| Alexion Pharmaceuticals, Inc. | 4 |
| Novartis Pharmaceuticals | 4 |
| ADARx Pharmaceuticals, Inc. | 1 |
| Amgen | 1 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Glomerulonephritis, Membranoproliferative? (10)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PEGCETACOPLAN (APL-2) | 5 |
| Danicopan | 3 |
| RITUXIMAB | 2 |
| Eculizumab | 2 |
| Telitacicept | 1 |
Showing 5 of 10 drugs.
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| TP10 | 1 |
| Aliskiren 150 | 1 |
| Cyclosporine 0.05% | 1 |
| Daratumumab SC | 1 |
| Iptcaopan 200 mg | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Glomerulonephritis, Membranoproliferative trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute kidney injury | 17 | 5 |
| Pneumonia | 4 | 3 |
| Pyrexia | 4 | 3 |
| Nephrotic syndrome | 3 | 2 |
| Dehydration | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Glomerulonephritis, Membranoproliferative? (36)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy: Randomized, Double-Blind Clinical Trial. | Journal of the American Society of Nephrology : JASN | 2025 | Yes |
| Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. | The New England journal of medicine | 2025 | Yes |
| Functional Magnetic Resonance Imaging to Monitor Disease Progression: A Prospective Study in Patients with Primary Membranoproliferative Glomerulonephritis. | Nephron | 2024 | Yes |
| Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. | American journal of nephrology | 2022 | Yes |
| Disentangling a Case of Glomerulonephritis with Fibrils. | Clinical journal of the American Society of Nephrology : CJASN | 2022 | Yes |
Showing 5 of 36 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Primary membranoproliferative glomerulonephritis | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
| Primary membranoproliferative glomerulonephritis | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Primary membranoproliferative glomerulonephritis | 54370 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Primary membranoproliferative glomerulonephritis | 54370 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.